LQDA Stock Overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.50|
|52 Week High||US$7.16|
|52 Week Low||US$2.25|
|1 Month Change||17.77%|
|3 Month Change||53.20%|
|1 Year Change||87.71%|
|3 Year Change||-63.33%|
|5 Year Change||n/a|
|Change since IPO||-50.45%|
Recent News & Updates
Liquidia And United: The Tango Continues
Liquidia's November tentative approval does not end the story. The 30-month stay will last until October 2022, or earlier if the Court decides faster. Liquidia has almost won the battle, but '066 still remains a hurdle.
|LQDA||US Pharmaceuticals||US Market|
Return vs Industry: LQDA exceeded the US Pharmaceuticals industry which returned 5.3% over the past year.
Return vs Market: LQDA exceeded the US Market which returned 4.2% over the past year.
|LQDA Average Weekly Movement||12.3%|
|Pharmaceuticals Industry Average Movement||10.6%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: LQDA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: LQDA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States.
Liquidia Fundamentals Summary
|LQDA fundamental statistics|
Is LQDA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LQDA income statement (TTM)|
|Cost of Revenue||US$2.53m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.75|
|Net Profit Margin||-376.78%|
How did LQDA perform over the long term?See historical performance and comparison
Is Liquidia undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LQDA ($5.5) is trading below our estimate of fair value ($64.2)
Significantly Below Fair Value: LQDA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LQDA is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: LQDA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LQDA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LQDA is overvalued based on its PB Ratio (3.9x) compared to the US Pharmaceuticals industry average (2.1x).
How is Liquidia forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LQDA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LQDA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LQDA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LQDA's revenue (46.7% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: LQDA's revenue (46.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LQDA's Return on Equity is forecast to be high in 3 years time
How has Liquidia performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LQDA is currently unprofitable.
Growing Profit Margin: LQDA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LQDA is unprofitable, and losses have increased over the past 5 years at a rate of 12.4% per year.
Accelerating Growth: Unable to compare LQDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LQDA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: LQDA has a negative Return on Equity (-53.59%), as it is currently unprofitable.
How is Liquidia's financial position?
Financial Position Analysis
Short Term Liabilities: LQDA's short term assets ($67.5M) exceed its short term liabilities ($7.1M).
Long Term Liabilities: LQDA's short term assets ($67.5M) exceed its long term liabilities ($20.3M).
Debt to Equity History and Analysis
Debt Level: LQDA has more cash than its total debt.
Reducing Debt: Insufficient data to determine if LQDA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LQDA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if LQDA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Liquidia current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LQDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LQDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LQDA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LQDA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LQDA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roger Jeffs (59 yo)
Dr. Roger A. Jeffs, Ph D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and also serves as its Chief Executive Officer. He serves as Co-Fou...
Experienced Management: LQDA's management team is considered experienced (2.3 years average tenure).
Experienced Board: LQDA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LQDA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.9%.
Liquidia Corporation's employee growth, exchange listings and data sources
- Name: Liquidia Corporation
- Ticker: LQDA
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$285.879m
- Shares outstanding: 51.98m
- Website: https://www.liquidia.com
Number of Employees
- Liquidia Corporation
- 419 Davis Drive
- Suite 100
- North Carolina
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/23 23:16|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.